Novogene Establishes its First European Genomic Sequencing Center in Cambridge, UK
Cambridge, UK – May 21, 2018 – Novogene, a leading global provider of genomics services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe.
The Novogene UK Genomic Sequencing Center will be equipped with a full automation system and the latest Illumina NovaSeq and supercomputing platforms. Establishing this facility will enable Novogene to provide cutting-edge next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies, and biotechnology companies.
“We are proud to set up our first European laboratory at the Babraham Research Campus,” said Dr. Ruiqiang Li, Founder and CEO of Novogene. “Our UK lab is our first step towards addressing the increasing demand from our European customers and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”
Derek Jones, CEO of Babraham Bioscience Technologies, which is responsible for the management and development of the Babraham Research Campus added: “I am extremely pleased to welcome Novogene to the Babraham Research Campus. The role of genomics is rapidly evolving and the Cambridge Cluster has become a hub for innovation in this area, attracting leader organizations, like Novogene, to locate here. Close proximity to academic and commercial collaborateors – both on campus and within the wider cluster – is hugely beneficial to the organizations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”
About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.
The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).
The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit: www.babraham.com.
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit en.novogene.com.
The Babraham Research Campus
Babraham Bioscience Technologies Ltd